NRP1 and neoplasm: Lin Zhao et al. designed a bifunctional fusion polypeptide Tat-C-RP7 with both NRP-1 targeting and anti-angiogenic activities, which have an excellent ability to penetrate the BBB and anti-tumor angiogenesis for the treatment of gliomas [23].